Display options
Cite
Shah NP, Wang Q, Wolski KE, et al. The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care. 2019;43(2):e22-e24doi: 10.2337/dc19-1117.
Shah, N. P., Wang, Q., Wolski, K. E., Cho, L., McErlean, E., Ruotolo, G., Weerakkody, G., Riesmeyer, J. S., Nicholls, S. J., Lincoff, A. M., Nissen, S. E., & Menon, V. (2020). The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes care, 43(2), e22-e24. https://doi.org/10.2337/dc19-1117
Shah, Nishant P, et al. "The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE." Diabetes care vol. 43,2 (2020): e22-e24. doi: https://doi.org/10.2337/dc19-1117
Shah NP, Wang Q, Wolski KE, Cho L, McErlean E, Ruotolo G, Weerakkody G, Riesmeyer JS, Nicholls SJ, Lincoff AM, Nissen SE, Menon V. The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care. 2020 Feb;43(2):e22-e24. doi: 10.2337/dc19-1117. Epub 2019 Dec 05. PMID: 31806654.
Copy Download .nbib Format: NLM
Share it on

Diabetes Care. 2020 Feb;43(2):e22-e24. doi: 10.2337/dc19-1117. Epub 2019 Dec 05.

The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE.

Diabetes care

Nishant P Shah, Qiuqing Wang, Katherine E Wolski, Leslie Cho, Ellen McErlean, Giacomo Ruotolo, Govinda Weerakkody, Jeffrey S Riesmeyer, Stephen J Nicholls, A Michael Lincoff, Steven E Nissen, Venu Menon

Affiliations

  1. Duke University School of Medicine, Durham, NC.
  2. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
  3. C5Research, Cleveland Clinic, Cleveland, OH.
  4. Eli Lilly and Company, Indianapolis, IN.
  5. MonashHeart, Monash University, Clayton, Australia.
  6. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH [email protected].

PMID: 31806654 DOI: 10.2337/dc19-1117

[No abstract available.]

Publication Types